Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196557 | 1.00 | GRM5 (0.43) | GRM5CYP1A2FADS1 | |
| SCHEMBL5852713 | 0.82 | VCAM1 (0.43) | GRM5CYP1A2 | |
| SCHEMBL56741 | 0.82 | GRM5 (0.43) | GRM5 | |
| SCHEMBL1421650 | 0.82 | GRM5 (0.47) | GRM5 | |
| SCHEMBL633226 | 0.82 | TSHR (0.50) | GRM5CYP1A2 | |
| SCHEMBL16953083 | 0.76 | RAPGEF4 (0.32) | — | |
| SCHEMBL16961799 | 0.76 | RAPGEF4 (0.32) | — | |
| SCHEMBL15094220 | 0.76 | RAPGEF4 (0.32) | — | |
| SCHEMBL17143891 | 0.76 | RAPGEF4 (0.32) | FADS1 | |
| SCHEMBL4452355 | 0.76 | KCNH2 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111668481-B | Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode | 北京科技大学 | 2021-12-03 | — | — | CN | claimed |
| CN-111668481-A | Preparation method of metal aluminum secondary battery with multi-group organic micromolecules as positive electrode | 北京科技大学 | 2020-09-15 | — | — | CN | claimed |
| EP-2284222-A2 | Semiconductor composition | Xerox Corporation (US) | 2011-02-16 | — | — | EP | claimed |
| US-20110031475-A1 | Semiconductor Composition | XEROX CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| CN-116969925-B | Heteroaryl-triazole compounds | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-28 | — | — | US | disclosed |
| EP-4709716-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4702016-A1 | PYRIMIDINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025215121-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-12441754-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000040524-A1 | PREPARATION OF NUCLEAR CHLORINATED AROMATIC COMPOUNDS | OCCIDENTAL CHEMICAL CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
| US-5981789-A | CHLORODENITRATING AROMATIC COMPOUNDS USING LESS CHLORINATING AGENT AND LOWER TEMPERATURES, THEN RECYCLING THE PRODUCT MIXTURE TO INCREASE THE YIELD | OCCIDENTAL CHEMICAL CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5098466-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | CTRL, PTMS, DDT | GRM5 516/4885CYP1A2 39/4885FADS1 3624/4885 |
| US-20250213558-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF | CACNA1G, CACNA1I, CACNA1H | GRM5 125/4885CYP1A2 3329/4885FADS1 3990/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | GRM5 3349/4885CYP1A2 2579/4885FADS1 1165/4885 |
| US-12441754-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | GRM5 2695/4885CYP1A2 1971/4885FADS1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.